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Abstract
This study explored the involvement of N-methyl-D-aspartate (NMDA) in the effects of mu opioid
agonists. A hot plate procedure was used to assess antinociception and tolerance in mice in which
the NR1 subunit of the NMDA receptor was reduced (knocked down, KD) to approximately 10%
and in mice treated with the NMDA antagonist, LY235959 [(−)-6-phosphonomethyl-deca-
hydroisoquinoline-3-carboylic acid]. The mu opioid agonists, morphine, l-methadone and
fentanyl, were approximately 3-fold less potent in the NR1 KD mice than in wild type (WT)
controls; however, the development of morphine tolerance and dependence did not differ
markedly in the NR1 KD and WT mice. Acute administration of the NMDA antagonist,
LY235959 produced dose-dependent, leftward shifts in the morphine dose-effect curve in WT
mice, but not in the NR1 KD mice. Chronic administration of LY235959 during the morphine
tolerance regimen did not attenuate the development of tolerance in the NR1 KD nor the WT
mice. These results indicate that the NR1 subunit of the NMDA receptor does not play a
prominent role in mu opioid tolerance.
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INTRODUCTION
In the central nervous system, glutamate is the most prominent excitatory neurotransmitter
and is known to work through several different receptor types, including three different
classes of ionotropic receptors: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and kainate as well as metabotropic glutamate
(mGlu) receptors. Among these receptor types, there is substantial evidence to support a
modulatory role for the NMDA receptor in the effects of opioids.
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Several laboratories have shown that NMDA receptor antagonists can potentiate the acute
antinociceptive effects of opioid agonists, both in squirrel monkeys (Allen and Dykstra,
2001; Allen et al., 2003) and rodents (Kozela and Popik, 2002; Nemmani et al., 2004; Craft
and Lee, 2005; Fischer et al., 2005; Grisel et al., 2005). Moreover, administration of NMDA
receptor antagonists in combination with morphine reduces the development of tolerance to
its antinociceptive effects (Allen and Dykstra, 1999; 2000; Trujillo, 2000; Bryant et al.,
2006; Mendez and Trujillo, 2008).
Despite a wealth of evidence implicating the involvement of NMDA receptors in morphine
antinociception and tolerance, the specific role of the NMDA receptor in mediating these
effects remains unclear. Studies with antagonists specific to the NMDA receptor represent
one way to investigate the role of NMDA receptors in morphine’s effects. Another way to
examine these interactions is to take advantage of genetically-modified mice. Therefore, the
current study examined the effects of mu-opioid agonists in mice with a hypomorphic allele
for the gene encoding the NR1 subunit of the NMDA receptor (Mohn et al., 1999). Whereas
mice with a full knockout of NR1 protein are not viable, the mice used here express
approximately 5–10% of the normal level of NR1, which is sufficient for survival into
adulthood. Consistent with the reduced NR1 gene expression, these mutants display less
than 10% of functional NMDA receptors in the brain, compared to WT controls. Therefore,
these NR1 knockdown (NR1 KD) mice provide a possible model for assessment of the role
of the NR1 subunit of the NMDA receptor in the neurobiology of the antinociceptive effects
of morphine.
Specifically, the present study used a hotplate nociceptive assay to measure the acute
antinociceptive effects of morphine and two other mu opioid agonists, l-methadone and
fentanyl. Effects of morphine were examined in NR1 KD mice and compared to WT
controls, as well as in mice that were treated both acutely and chronically with the NMDA
antagonist, LY235959 [(−)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboylic acid].
The hotplate procedure was selected here in order to make direct comparisons with data
collected previously in mice that had been treated with NMDA antagonists. In addition, the
development of tolerance to and dependence upon morphine was examined in NR1 KD and
WT mice. Based on the results of several studies reporting that NMDA antagonists can
increase the antinociceptive effects of morphine under certain conditions, as well as
attenuate the development of opioid tolerance, we hypothesized that similar effects would be
observed in mice in which the NR1 subunit was knocked down.
METHODS
Subjects
Adult male homozygous NR1 receptor deficient mice and wildtype controls were either
provided by Dr. Beverly Koller (UNC, Department of Genetics) or bred and genotyped in
the animal facilities of the Psychology Department at the University of North Carolina at
Chapel Hill. All mice were generated as described previously (Mohn et al., 1999) and
weighed between 23 and 34 g when experiments were conducted. Previous investigations
have characterized these mice as NR1 hypomorphs, given that the NR1 gene is not
eliminated in these mice, but rather under-expressed. Previous investigations indicate that
the NR1 subunit is greatly reduced in all brain regions of these mutant mice (Duncan et al.,
2002). The behavioral phenotype of these mice includes reduced habituation in activity
chambers (Mohn et al., 1999) as well as increased acoustic startle responses and deficits in
prepulse inhibition (Duncan et al., 2004).
The mice were group housed 4–5/cage in standard Plexiglas cages in a colony room
maintained on a 12-hr reversed light/dark cycle (lights off at 07:00h). All mice had
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continuous access to food and water throughout the study. Mice were also handled and
adapted to the testing environment for two days prior to initiation of an experiment. All
testing procedures were conducted between 09:00 and 14:00h. Animals used in this study
were cared for in accordance with the guidelines of the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill and the 2010 Guidelines for
the Care and Use of Laboratory Animals of the National Institutes of Health (NIH).
Antinociceptive procedure
Antinociception was assessed using a hot plate analgesia meter (25.3 × 25.3 cm) (Columbus
Instruments, Columbus, OH) maintained at 56±0.1°C. The antinociceptive response was
evaluated by recording the latency to lick or flutter the hind paw(s), or to jump from the
hotplate surface. Responses were measured using a stopwatch to the nearest 0.1 sec. To
prevent tissue damage, a cutoff time of 20 s was defined as the maximal response.
Immediately following the termination of a trial, mice were removed from the hotplate
surface.
An additional experiment was run in order to determine whether the NR1 receptor
knockdown mice and their wild type littermates differed in their baseline responses on the
hot plate. In this experiment, responses to a full range of temperatures were examined in
NR1 KD and WT mice, from 44 ±0.1°C to 56±0.1°C.
Baseline response latencies on the hot plate were determined twice prior to the beginning of
drug administration and spaced 30 min apart. Data from these determinations were averaged
to yield one baseline value. Following baseline latency measurements, responding on the hot
plate was examined over multiple cycles, spaced either 15 min (fentanyl) or 30 min
(morphine, l-methadone) apart. Drugs were administered at the start of each cycle and
latency on the hot place was determined during the last min of the cycle. Drug doses were
increased cumulatively, with the dose administered increasing in one-quarter or one-half log
unit increments prior to each cycle.
Tolerance Regimen
Data collected during the acute phase of the study (described above) indicated that the
ED50s for morphine in the NR1 KD mice were larger than those in the WT mice. Therefore,
the tolerance regimen was adjusted based on individual sensitivities of the WT and NR1 KD
mice, rather than the administration of the same dose of morphine to all mice. The
appropriateness of employing a tolerance regimen which is adjusted to each animal’s
individual sensitivity is described by Barrett et al. (2001).
Specifically, morphine dose-effect curves were first obtained on the morning of day 1
(prechronic). On the basis of these prechronic morphine dose-effect curves, an individual
ED50 value was determined for each mouse. The tolerance regimen was then initiated, with
morphine doses adjusted on the basis of each mouse’s prechronic ED50 value. According to
this regimen, each mouse received 5× its individual ED50 on the morning and evening of
day 2; 10× its individual ED50 on the morning and evening of day 3; 15× its individual
ED50 on the morning and evening of day 4 and 20× its individual ED50 on the morning and
evening of days 5–13. On the next day (day 14), the postchronic morphine dose-effect curve
was determined, coinciding with the time of the regularly scheduled morning injection.
Given this regimen, it should be noted that the NR1 KD mice actually received larger
absolute doses than the WT mice; however, the functional dose was the same for each
mouse.
In an additional set of experiments, mice received a dose of 1.0 mg/kg of LY235959
throughout the tolerance regimen. These experiments paralleled the tolerance regimen
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described above. That is, on day one, a morphine dose-effect curve was determined for each
mouse and individual ED50 values were calculated. The tolerance regimen was then
initiated, based on each mouse’s ED50 value; however, mice received 1.0 mg/kg of the
NMDA antagonist, LY235959, in combination with increasing doses of morphine
throughout the 12 day morphine tolerance regimen as well as on test day.
Withdrawal Jumping
Immediately after determining the postchronic morphine dose-effect curve, mice were given
an additional morphine injection to raise their cumulative morphine levels to 20 × their
original ED50. Naltrexone (1.0 mg/kg) was administered 30 min later, and mice were placed
in 4 L glass beakers (Pyrex, Lowell MA, USA) for a 30 min period. The number of jumps,
paw flutters and “wet-dog shakes” were recorded for each 5-min interval.
Drugs
Morphine sulfate was provided by the National Institute on Drug Abuse (Bethesda, MD,
USA); l-methadone and LY235959 by Lilly Research Laboratories (Indianapolis, IN, USA)
or purchased from Tocris Bioscience (Ellisville, MO, USA). Fentanyl and naltrexone were
purchased from Sigma Chemical Co (St. Louis, MO, USA). Drugs were dissolved in 0.9%
saline or distilled water to yield all concentrations. All doses were injected subcutaneously
at a volume of 0.1 ml/10 g.
Data analysis
Drug effects were expressed as a percentage of the maximal possible effect (%MPE) using
the following formula:
Data are expressed as the mean %MPE (± S.E.M.). ED50 values and 95% confidence limits
were calculated using PHARM/PCS version 4 (Tallarida and Murray, 1987). When
appropriate, statistical analyses were conducted using a t-test or repeated-measures analysis
of variance (ANOVA). Post-hoc tests were then conducted to assess the specific group
differences. Fisher's protected least significant difference (PLSD) analysis was conducted to
determine points that were significantly different from baseline. All analyses were
conducted with an alpha level of significance set at p≤ 0.05.
RESULTS
Fig. 1 shows a temperature-effect curve for NR1 KD mice and the WT controls. ANOVA
confirmed an effect of temperature, but no effect of genotype. Pairwise comparisons of the
temperature effects indicated that response latencies at the lower temperatures (i.e., 46°, 48°
and 50°C) were significantly different (p<0.05) from the response latencies at the higher
temperatures (i.e., 52°, 53° and 56°C). No differences were observed in baseline response
latency between NR1 KD and WT mice across all temperatures [F(1,25)=1.19, NS].
Similarly, a separate examination of baseline response latencies on a 56°C hot plate over a
2-hr test period, revealed no differences between the genotypes following saline
administration [F(1,19)=3.03, p=.098] (data not shown). Although response latencies did not
differ between the NR1 KD and WT mice when examined on the hot plate, informal
observations indicated that the NR1 KD mice did show increased activity levels in their
cages and also when they were handled for injections.
Dykstra et al. Page 4













Fig. 2 shows the effects of morphine, l-methadone and fentanyl in the NR1 KD mice and
their WT controls. The ED50 value (95% confidence limits) for morphine in WT mice was
2.54 mg/kg (1.76 – 3.67) and 10.39 mg/kg (8.57 – 12.40) in the NR1 KD mice, yielding a
potency ratio of 4.09, indicating that morphine was approximately 4 times more potent in
WT mice than in the NR1 KD mice. The effects of l-methadone were similar to those
observed with morphine, with l-methadone being approximately 4 times more potent in the
WT mice than in NR1 KD mice (potency ratio =3.85). Specifically, the l-methadone ED50
value (95% confidence limits) was 1.02 mg/kg (0.72 – 1.44) in the WT mice and 3.93 mg/kg
(3.03 – 5.09) in the NR1 KD mice. The profile of effects obtained for fentanyl was similar to
those observed with morphine and l-methadone. That is, the ED50 for fentanyl in the WT
mice was 0.05 mg/kg (0.04 – 0.06), whereas the ED50 for fentanyl in the NR1 KD mice was
0.12 mg/kg (0.11 – 0.14), yielding a potency ratio of 2.36 (1.93 – 2.89). In both groups of
mice, fentanyl was more potent than methadone, which was more potent than morphine.
Morphine and l-methadone dose-effect curves were subsequently redetermined following
pretreatment with the opioid receptor antagonist naltrexone. A dose of 1.0 mg/kg naltrexone
attenuated the antinociceptive effects of both morphine and l-methadone in a comparable
manner, producing a 3 to 5-fold rightward shift in the morphine and l-methadone dose-effect
curves in both NR1 KD and WT mice. The ED50 (95% confidence limits) values for
morphine and l-methadone alone and in combination with naltrexone are shown in Table 1.
Fig. 3 shows the effects of morphine following a regimen of chronic morphine
administration. The effects of morphine prior to tolerance induction were similar to those
shown in Fig. 2. That is, morphine produced dose-dependent increases in latency to respond
on the hot plate in both NR1 KD and WT mice; however, morphine was less potent in the
NR1 KD mice, yielding an ED50 of 7.79 mg/kg (5.86 – 10.36) in the NR1 KD mice and an
ED50 of 2.88 mg/kg (2.18 – 3.80) in the WT mice. Following 12 days of chronic morphine
administration, with the dose of morphine increased by the same proportion in each
individual mouse, the morphine dose-effect curve shifted to the right, yielding an ED50 of
30.15 mg/kg (23.54 – 38.61) in the NR1 KD mice and an ED50 of 9.06 mg/kg (7.16 –
11.47) in the WT mice, with the magnitude of the shift in the morphine dose-effect curve
being approximately the same, i.e., 3.1 – 3.9 fold in the WT and NR1 KD mice,
respectively.
After the post chronic morphine dose-effect curve was determined, mice were administered
naltrexone and observed for signs of withdrawal. During the 30-min observation period,
typical signs of withdrawal were observed in both WT and NR1 KD mice, including
occasional paw tremors and wet dog shakes. The most prominent sign of withdrawal,
jumping behavior, is shown in Fig. 4 averaged over a 15-min or a 30-min observation
period. The number of jumps that occurred during the first 15-min period of the 30-min
observation period were significantly less in the NR1 KD mice as compared to the WT mice
(p=.05); however, when the data were averaged across the entire 30-min period, no
significant differences were observed between the genotypes (p=.34).
Fig. 5 shows the effects of acute pretreatment with the competitive NMDA receptor
antagonist, LY235959 on the morphine dose-effect curve in both WT and NR1 KD mice.
The ED50 for morphine alone was 5.54 mg/kg (4.57 – 6.72) in the WT mice (top) and 9.22
mg/kg (6.82 – 12.47) in the NR1 KD mice (bottom). LY235959 did not produce consistent
shifts in the morphine dose-effect curve in the NR1 KD mice; however, it did produce
leftward shifts in the morphine dose-effect curve in the WT mice. Specifically, the morphine
ED50 was 2.82 mg/kg (2.11 – 3.79) following 0.32 mg/kg of LY235959 and 2.02 mg/kg
(1.32 – 3.10) following 1.0 mg/kg of LY235959.
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Table 2 shows the effects of chronic administration of 1.0 mg/kg LY235959 throughout the
tolerance regimen and on test day. The effects of morphine prior to and subsequent to the
development of tolerance were similar to those observed previously. That is, following 12
days of morphine administration in mice that received saline concurrently, the morphine
ED50 increased 2.59 and 2.80 fold, in the NR1 KD and WT mice, respectively. In separate
groups of NR1 KD and WT mice that received a 1.0 mg/kg dose of LY235959 throughout
the tolerance regimen, the morphine ED50 increased 3.24 and 7.03 fold, in the NR1 KD and
WT mice, respectively. Therefore, rather than attenuating the development of morphine
tolerance, as hypothesized, it appears that chronic administration of 1.0 mg/kg of LY235959
either did not shift the morphine curve or actually shifted the morphine curve further to the
right.
DISCUSSION
The present study employed mice with significantly reduced NR1 subunit expression to
examine the role of the NMDA receptor system in mediating the acute antinociceptive
effects of a range of opioid agonists as well as the development of tolerance and dependence
upon morphine.
Results from the current study regarding the antinociceptive effects of mu opioids in WT
mice indicate that fentanyl is more potent than methadone, which is more potent than
morphine. This potency relationship is in agreement with well-established findings
regarding the efficacy of mu opioids (e.g., Colpaert and Niemegeers, 1975; Colpaert et al.,
1976). The same potency relationship was observed in the NR1 KD mice; however, all three
mu opioid agonists were approximately 2–4 times less potent in the NR1 KD mice than the
WT mice.
The differences in mu opioid potency between the NR1 KD and WT mice cannot be
explained by differences in baseline sensitivities since the NR1 KD and WT mice were
equally sensitive to a range of temperatures on the hot plate. This observation agrees with
another study in which paw withdrawal latencies in response to a noxious thermal stimulus
were not different in cortex-specific NR1 knockout mice and C57BL/6 control mice;
however, cortex-specific NR1 KD mice did show less nociception than the control mice in a
formalin test (Quintero et al., 2007). Moreover, it has been shown that a conditional deletion
of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces pain in
response to injury (South et al., 2003).
The fact that no differences in baseline nociception were observed in the present study, in
which the hot plate procedure was used to assess antinociception, may be due to the type of
procedure used to examine antinociception or to differences in the specificity of alterations
of the NR1 subunit. For example, the studies referred to above (Quintero et al., 2007; South
et al., 2003) that have reported decreased nociception in NR1 KD mice in comparison to
control mice have examined situations involving tonic nociception (e.g., formalin test; injury
induced pain) versus nociception in response to an acute thermal stimulus, as employed in
the present study. Moreover, these same studies have examined mice with a conditional and/
or cortex-specific deletion of the NR1 subunit rather than a global knockdown of up to 90%,
as was the case in the present study.
Although the mu opioids examined here were less potent in the NR1 KD mice than in the
WT mice, the mice did not differ when other aspects of opioid pharmacology were
examined. The effects of both morphine and l-methadone were antagonized by naltrexone to
an equivalent degree in the NR1 KD and WT mice; morphine tolerance developed to the
same extent in both NR1 KD and WT mice, and although there was some suggestion that
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signs of physical withdrawal may have occurred somewhat later in the NR1 KD mice than
the WT mice, differences in withdrawal jumping were not significant when withdrawal
jumps were observed over a longer time period. Taken together, these data suggest that the
mu opioid receptor system is not altered in NR1 KD mice.
The findings regarding the development of morphine tolerance are particularly interesting
because previous research has shown that NMDA antagonists can attenuate the development
of tolerance. (e.g., Allen and Dykstra, 1999; 2000; Trujillo, 2000; Bryant et al., 2006;
Mendez and Trujillo, 2008). Based on these findings, we had predicated that tolerance
would be attenuated in the NR1 KD mice. In this context, it is important to emphasize the
way in which the tolerance regimen was carried out in the present study.
Typically, when the development of tolerance is examined between different groups of
animals, each group receives the same dose and/or administration schedule during a chronic
regimen and then post chronic dose effect curves are compared between groups. Since
morphine was less potent in the NR1 KD mice, as compared to WT mice, the tolerance
regimen in the present study was adjusted, based upon individual morphine ED50s obtained
in the WT and NR1 KD mice. As a result, the NR1 KD mice actually received a greater
absolute dose of morphine throughout the tolerance regimen, given that their prechronic
ED50s were approximately 3 times larger than the ED50s obtained in the WT mice. Since it
is well-established that the magnitude of morphine tolerance is greater when larger doses of
morphine are administered (Adams and Holtzman, 1990; Hoffman et al., 1998; Colpaert,
1996), one might expect to see a greater degree of tolerance with the NR1 KD mice since
they actually received a larger amount of morphine during the tolerance regimen.
Nevertheless, tolerance developed to an equivalent degree in both the NR1 KD and WT
mice, with the ED50s increasing approximately 3-fold in both the NR1 KD and the WT
mice.
At least one other study that examined the development of morphine tolerance in mice
lacking the gene encoding the GluRε1 subunit of the NMDA receptor (also referred to as the
NR2 subunit) reported that morphine tolerance was attenuated in the genetically-modified
mice as compared to C57BL/6J mice (Inoue et al., 2003). Nevertheless, the dose of
morphine used in the Inoue et al. study to establish tolerance (10 mg/kg) was the same in
both groups, even though the mice lacking the NMDA receptor GluRε1 (or NR2) subunit
gene were more sensitive to the antinociceptive effects of morphine than the C57BL/6J
controls. Therefore, when comparing the development of tolerance between groups of mice
that differ in some way, it is important to accommodate these differences by adjusting the
amount of drug administered during the tolerance regimen, based on the acute sensitivity of
animals within each group (see Barrett et al., 2001 for a discussion of this issue).
It is also interesting that the differences in potency observed between the NR1 KD mice and
their WT littermates were actually in the opposite direction than what was predicted, based
on previous studies in our laboratory examining the acute effects of morphine in
combination with a range of NMDA antagonists. Indeed, our laboratory has shown that
doses of the NMDA antagonist, LY235959 that had no antinociceptive effects when
examined alone, produce leftward shifts in the morphine dose effect curve in both squirrel
monkeys (Allen and Dykstra, 2001) and mice (Fischer and Dykstra, 2006). This observation
was also replicated in the current study in which doses of 0.32 and 1.0 mg/kg of LY235959
shifted the morphine dose-effect curve to the left in wild type mice; however, no shifts were
observed in the NR1 KD mice.
There are a number of reasons why differences might be observed between the acute effects
of an NMDA antagonist and the prolonged reduction in NMDA receptor function through
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genetic manipulation. The NR1 KD mice examined in the present study have been described
as NR1 hypomorphs given that NR1 binding sites in these mice show both a marked and a
global reduction (Mohn et al., 1999; Duncan et al., 2002). Therefore, acute administration of
an NMDA antagonist is likely to produce different effects than what might occur when
receptor function undergoes long term reduction. In NR1 KD mice, NMDA receptor
function is impaired throughout development and remains through adulthood. Clearly, this
provides many opportunities for compensatory functions to develop. Indeed, the relatively
subtle nature of the metabolic alterations observed in NR1 KD mice, despite a marked
reduction in the expression of the NR1 subunit, suggests the presence of compensatory
responses (Duncan et al., 2004).
Secondly, although the NR1 subunit is a critical component of the entire NMDA receptor
complex, the consequences of a 90% reduction in the NR1 subunit upon other subunits of
the NMDA receptor is not well known. For example, significant global reductions in NR2A
and NR2B protein levels have been reported in NR1 KD mice (Ramsey et al., 2008). Mice
deficient in the NR2A subunit (also called the GluRε1 subunit) of the NMDA receptor did
not reveal altered responses to painful stimuli in assays of allodynia or hyperalgesia
(Petrenko et al., 2003); however, the antinociceptive effects of morphine in a tail pinch
procedure were enhanced in the NR2A (or GluRε1) deficient mice (Inoue et al., 2003).
Clearly, additional data are required to determine the contribution of each of these variables
(i.e., the specific NR subunit examined, type of analgesic procedure employed, etc.) to
interactions between opioid receptor function and the NMDA system.
Finally, the current study suggests that the withdrawal signs following chronic
administration of morphine were not different between the WT and NR1 KD mice. These
findings are similar to those reported by Glass et al., (2008) in which they showed that
bilateral local NR1 gene deletion did not alter either the somatic or visceral symptoms of
withdrawal precipitated by naloxone in morphine-treated mice.
The results obtained here indicate that alterations in mu opioid antinociception and tolerance
in NR1 KD mice do not parallel the effects produced by either the acute or chronic
administration of an NMDA antagonist. Taken together these results suggest that mu opioid
receptor function is not changed in mice that express low levels of the NR1 subunit of the
NMDA receptor.
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Temperature-dependent effects on the hot plate in NR1 KD and WT mice. Horizontal axis:
hot plate temperature in degrees Celsius. Vertical axis: latency to respond on the hot plate in
seconds. Temperature-effect determinations were conducted at 15-min intervals. (n = 7 or 8)
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Dose-effect curves for morphine (0.32–32 mg/kg), l-methadone (0.32–10 mg/kg) or fentanyl
(0.01–0.3 mg/kg) in NR1 KD and WT mice. Horizontal axis: dose of morphine, l-methadone
or fentanyl in milligrams per kilogram. Vertical axis: antinociception quantified as %MPE.
Dose-effect determinations were conducted cumulatively at 30-min (morphine and l-
methadone) or 15min (fentanyl) intervals. (n = 6 or 7).
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Dose-effect curves for morphine, prior to and following a regimen of chronic administration
of morphine for 12 days in WT (top) and NR1 KD (bottom) mice. Horizontal axis: dose of
morphine in milligrams per kilogram. Vertical axis: antinociception quantified as %MPE.
Dose-effect determinations were conducted cumulatively at 30-min intervals. (n = 8).
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Withdrawal jumping in morphine-tolerant mice following administration of 1.0 mg/kg of
naltrexone. Data are averaged across two different time periods, either a 15-min or a 30-min
observation period. Horizontal axis: data from WT or NR1 KD mice. Vertical axis: total
jumps observed during the first 15-min observation period (top) or total jumps observed
during the entire 30-min observation period (bottom). Asterisk indicates a significant effect
of genotype (p=0.05). (n = 7 or 8)
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Dose-effect curves for morphine (0.32–18 mg/kg) in combination with LY235959 (0.1–1.0
mg/kg) in NR1 WT (top) and NR1 KD (bottom) mice. Horizontal axis: dose of morphine in
milligrams per kilogram. Vertical axis: antinociception quantified as %MPE. Dose-effect
determinations were conducted cumulatively at 30-min intervals. Points above “C” represent
tests after saline or LY235959 administration. (n = 8)
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Table 1
ED50 values in mg/kg (± 95% confidence limits) and dose ratios for morphine and l-methadone alone and in
combination with 1.0 mg/kg naltrexone






Morphine WT 2.54 (1.76 – 3.67) 9.67 (8.04 – 11.60) 3.87 (2.69 – 5.53)
NR1 KD 10.39 (8.47 – 12.73) 32.54 (26.59 – 39.81) 3.12 (2.38 – 4.10)
l-Methadone WT 1.02 (0.72 – 1.44) 5.79 (4.29 – 7.83) 5.81 (3.60 – 8.85)
NR1 KD 3.93 (3.03 – 5.09) 12.14 (9.09 – 16.20) 3.10 (2.16 – 4.23)
1
C.L.=95% confidence limits
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Table 2









WT saline n=11 4.59 (3.79–5.56) 12.25 (9.20–16.31) 2.80 (2.02–3.85)
LY235959 n=11 1.91 (1.48 – 2.48) 13.14 (10.43–16.55) 7.03 (5.05–10.28)
NR1 KD saline n=8 10.30 (8.28–12.80) 24.21 (11.72–50.04) 2.59 (1.56–4.19)
LY235959 n=9 9.85 (7.66–12.67) 31.97 (18.88–54.11) 3.24 (1.97–5.35)
1
C.L.=95% confidence limits
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